Literature DB >> 17021315

The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration.

Robert Steinbrook1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17021315     DOI： 10.1056/NEJMp068185

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  64 in total

1.  Treatment of exudative age-related macular degeneration: many factors to consider.

Authors:  Timothy W Olsen
Journal:  Am J Ophthalmol       Date:  2007-08       Impact factor: 5.258

2.  Development trends for therapeutic antibody fragments.

Authors:  Aaron L Nelson; Janice M Reichert
Journal:  Nat Biotechnol       Date:  2009-04       Impact factor: 54.908

3.  Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).

Authors:  Roberta P A Manzano; Gholam A Peyman; Palwasha Khan; Petros E Carvounis; Muhamet Kivilcim; Min Ren; Jonathan C Lake; Patricia Chévez-Barrios
Journal:  Br J Ophthalmol       Date:  2006-12-19       Impact factor: 4.638

4.  Funding a clinical trial: the perspective of a medicines funder.

Authors:  Peter Alsop; Scott Metcalfe; Jackie Evans
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 5.  Therapeutic antibodies in ophthalmology: old is new again.

Authors:  Charlotte Magdelaine-Beuzelin; Coralie Pinault; Gilles Paintaud; Hervé Watier
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

Review 6.  Genetic diversity and medicinal drug response in eye care.

Authors:  Barkur S Shastry
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-05       Impact factor: 3.117

7.  VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy.

Authors:  Renhai Cao; Yuan Xue; Eva-Maria Hedlund; Zhaodong Zhong; Katerina Tritsaris; Barbara Tondelli; Franco Lucchini; Zhenping Zhu; Steen Dissing; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

8.  Constitutive and oxidative-stress-induced expression of VEGF in the RPE are differently regulated by different Mitogen-activated protein kinases.

Authors:  Alexa Klettner; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-15       Impact factor: 3.117

Review 9.  Lipid-based drug delivery systems in the treatment of wet age-related macular degeneration.

Authors:  Joanne D Du; Wye-Khay Fong; Suzanne Caliph; Ben J Boyd
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

10.  Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration.

Authors:  Saad Shaikh; John C Olson; Preston P Richmond
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.